← Human Trials & Peer-Reviewed Studies
the Effect of Oral Vasopressors for Liberation From IV Vasopressors in Spinal Shock
Plain-language guide to NCT04586790: phase 2 randomized trial of Desmopressin, 90 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT04586790
- Phase
- phase 2
- Status
- status unknown
- Start
- 2020-10-15
- Completion (planned or actual)
- 2021-01-01
- Participants
- 90 (estimated)
- Design
- randomized, open label (everyone knows who gets what), treatment
- Conditions studied
- Spinal Shock
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (phase 2) is built around Desmopressin.
It had three arms (groups): midodrine group (experimental), minirin group (experimental) and control group (experimental).
The patients will receive IV nor-adrenaline and are gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
The registry classes the interventions as drug.
Who Took Part
90 planned participants were the target.
It was open to people of any sex aged from 18 years up to 60 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Age of 18 - 60 years. Patients of both genders. Patients diagnosed by spinal shock and they are in the recovery stage .
The full record lists 3 inclusion and 3 exclusion criteria; among the exclusions: patient refusal; anuric or oliguric patients or patients with chronic kidney disease; patients with allergy to medication included in the study.
How the Study Was Run
The set-up was randomized, parallel-group and open-label.
Because people in this Desmopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Groups ran in parallel: each of the participants stayed in one arm throughout.
Nothing was hidden in this open-label Desmopressin study: the participants and staff both knew the treatment.
It started in 2020-10-15 with completion listed for 2021-01-01.
It ran at 1 site in Egypt.
Its stated primary purpose is treatment.
What Was Measured
Primary outcome: liberation the patient from IV vasopressors with maintaining hemodynamics (time frame: 48 hrs).
What This Means in Plain Language
Put simply, this is a phase 2, randomized trial of Desmopressin in 90 people.
Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Desmopressin compound page, all human trials.
Our Notes on the Compound
Desmopressin: A synthetic vasopressin analog (DDAVP) used for bedwetting, diabetes insipidus and some bleeding disorders.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.